Harrow Inc (HROW)

NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA

Harrow Inc is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.

Harrow Inc provides ophthalmic disease management solutions in North America, offering FDA-approved eye care products treating conditions such as dry eye disease, age-related macular degeneration, glaucoma, and cataracts. The company markets medications to eyecare professionals and patients across the U.S. and Canada, and operates ImprimisRx, a compounding facility serving eyecare prescribers.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Harrow Inc stock.

Our verdict on HROW

Overvalued: intrinsic value $8.75 per share, market price $29.52, margin of safety -237.5% (as of 2026-11-17).

Discounting its cash flows at 13.2% (average of 2 methods) values the shares at $8.75; the price of $29.52 is 237% above that value, and 65% of that value comes from beyond year five.

ETFs with the most weight in HROW

17 more funds hold it; the full list is part of the paid plan.

More on HROW

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Cheaper than HROW in Drug Manufacturers - Specialty & Generic

26 more in this industry show a wider margin of safety.

Is HROW undervalued or overvalued?

HROW is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 13.2% (average of 2 methods) values the shares at $8.75; the price of $29.52 is 237% above that value, and 65% of that value comes from beyond year five.

What is the intrinsic value of HROW?

$8.75 per share (as of the 2026-11-17 close), against a market price of $29.52. That is a margin of safety of -237.5%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.